Press Release: Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease

Core Insights - The FDA has granted Breakthrough Therapy designation to venglustat for treating neurological manifestations of type 3 Gaucher disease (GD3), highlighting its potential in addressing a significant unmet medical need [1][5][6] Group 1: Product and Clinical Data - Venglustat is an investigational oral glucosylceramide synthase inhibitor (GCSi) designed to reduce the accumulation of glycosphingolipids (GSLs) in the central nervous system (CNS) [4][8] - The LEAP2MONO phase 3 study showed that patients receiving venglustat had statistically significant improvements in neurological symptoms compared to those receiving enzyme replacement therapy (ERT), with a p-value of 0.007 [2][7] - Common adverse events reported in the study included headache (14.3% for venglustat vs. 18.2% for ERT), nausea (14.3% vs. 4.5%), spleen enlargement (14.3% vs. 0%), and diarrhea (14.3% vs. 0%) [2] Group 2: Disease Background - Gaucher disease (GD) is a rare inherited lysosomal storage disorder caused by a deficiency of glucocerebrosidase, leading to GSL accumulation in various organs [3] - GD3 is characterized by slower progression and variable symptom severity, with neurological symptoms being a significant concern [3][4] Group 3: Regulatory and Future Plans - Sanofi plans to pursue global regulatory filings for venglustat in GD3 during 2026, following its previous fast-track and orphan designations from the FDA [5] - The Breakthrough Therapy designation aims to expedite the development and review of medicines targeting serious conditions, requiring preliminary clinical evidence of substantial improvement over existing treatments [6]